Compare CRNX & HCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRNX | HCC |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Coal Mining |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.7B |
| IPO Year | 2018 | 2017 |
| Metric | CRNX | HCC |
|---|---|---|
| Price | $36.66 | $92.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $76.75 | ★ $95.29 |
| AVG Volume (30 Days) | ★ 1.3M | 782.1K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.36% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.37 |
| Revenue | $1,039,000.00 | ★ $1,310,043,000.00 |
| Revenue This Year | $720.10 | $59.95 |
| Revenue Next Year | $184.67 | $8.77 |
| P/E Ratio | ★ N/A | $61.71 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $43.14 |
| 52 Week High | $57.99 | $105.35 |
| Indicator | CRNX | HCC |
|---|---|---|
| Relative Strength Index (RSI) | 45.46 | 61.60 |
| Support Level | $33.19 | $85.21 |
| Resistance Level | $37.23 | $100.73 |
| Average True Range (ATR) | 2.17 | 3.48 |
| MACD | -0.18 | 0.39 |
| Stochastic Oscillator | 28.47 | 90.39 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Warrior Met Coal Inc produces and exports met or steelmaking coal, which is used as a component for steel production by metal manufacturers in Europe, South America, and Asia. The company is involved in longwall mining operations in its underground mines based in Alabama, Mine No. 4, Mine No. 7, and Blue Creek. Additionally, its natural gas operations remove and sell natural gas from owned and leased coal seams by reducing natural gas levels in its mines. The company generates revenue mainly through the production of steelmaking coal for sale to the steel industry. Geographically, the firm generates maximum revenue from its customers in Asia, followed by Europe, South America, and the United States.